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1246Objective: Cardiopulmonary bypass is known to induce systemic inflammatory responses that injure multiple
organs, especially the lungs. Activated protein C has been demonstrated to play an important role in the regulation
of inflammation in addition to coagulation.We investigated the anti-inflammatory effects of activated protein C in
a rat model of cardiopulmonary bypass.
Methods: Rats were randomized to receive an intravenous bolus of vehicle (control), 0.1 mg/kg diisopropyl
fluorophosphate-activated protein C, or 0.1 mg/kg activated protein C 10 minutes before the initiation of cardio-
pulmonary bypass. Rats underwent cardiopulmonary bypass for 60 minutes followed by another 60-minute
observation.
Results: The activated protein C group showed significantly higher mean arterial oxygen pressure and lower
mean lung wet-to-dry weight ratio after cardiopulmonary bypass than the control and diisopropyl
fluorophosphate-activated protein C groups. Furthermore, lung pathology revealed minimal inflammatory change
in the activated protein C group. A marked increase in CD11b expression and a decrease in CD62L expression
after cardiopulmonary bypass were observed in the control and diisopropyl fluorophosphate-activated protein C
groups. However, administration of activated protein C significantly attenuated these changes. Lung content of
tumor necrosis factor-a and interleukin-1b in the activated protein C group tended to be lower than in the other
groups. Lung content of macrophage inflammatory protein-2 in the activated protein C group was significantly
lower than in the diisopropyl fluorophosphate-activated protein C group.
Conclusions: Administration of activated protein C before cardiopulmonary bypass attenuates acute lung injury
induced by cardiopulmonary bypass at least in part through the inhibition of neutrophil activation and possibly via
the attenuation of proinflammatory cytokine production in this rat model of cardiopulmonary bypass. (J Thorac
Cardiovasc Surg 2011;141:1246-52)Cardiopulmonary bypass (CPB) is a common procedure in
heart surgery. Despite advances in surgical procedures and
material technology, CPB induces both coagulopathy and
inflammation when blood touches the bypass circuit. Be-
cause the lung is vulnerable to attack by neutrophils, CPB
is often followed by pulmonary dysfunction, which varies
widely, ranging from a clinically undetectable condition to
the most severe form, acute respiratory distress syndrome.1
These responses are associated with endotoxin release; ac-
celerated thrombin generation; activation of complement,
leukocytes, and platelets; and the production of cytokines
and other inflammatory mediators.2-5 This complex chain
of events seems to have similarities to sepsis, whiche Department of Regenerative Medicine and Tissue Engineering,a National
ral and Cardiovascular Center Research Institute, Osaka, Japan; and Depart-
of Cardiovascular Surgeryb and Organ Transplantation,c National Cerebral
ardiovascular Center, Osaka, Japan.
res: Authors have nothing to disclose with regard to commercial support.
d for publication March 14, 2010; revisions received April 21, 2010; accepted
blication May 31, 2010; available ahead of print July 5, 2010.
for reprints: Michiharu Suga, MD, PhD, Director, Department of General
cic Surgery, Takatsuki Red Cross Hospital, 1-1-1 Abuno, Takatsuki, Osaka
096, Japan (E-mail: michisuga@oo.em-net.ne.jp).
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.05.043
The Journal of Thoracic and Cardiovascular Surresults from a generalized inflammatory and procoagulant
response to an infection.6 These findings raise the possibility
that adequate regulation of coagulation and inflammation
may prevent CPB-induced lung injury, which is strongly
related to an adverse outcome.1
Activated protein C (APC) is an important natural antico-
agulant that is generated from protein C by the action of the
thrombin-thrombomodulin complex on the endothelial cell.7
APC inactivates factors Va and VIIIa, and neutralizes the ac-
tivity of plasminogen activator inhibitor-1, thereby increas-
ing fibrinolysis. Apart from the anticoagulant effects of
APC, its direct anti-inflammatory properties have recently
been identified.7 In vitro studies demonstrated that APC
down-regulates proinflammatory cytokines, such as inter-
leukin (IL)-6, IL-8, and tumor necrosis factor (TNF)-a re-
lease, from both endothelial cells and leukocytes through
a specific surface molecule, endothelial protein C receptor
(EPCR).13,16 In addition, expression of intercellular
adhesion molecule (ICAM)-1 stimulated by IL-1b and
TNF-a was suppressed by APC.12 In animal models, APC
reduced ischemia–reperfusion injury in a variety of organs
by inhibiting monocyte activation and cytokine-induced
neutrophil chemoattractant expression.8-11 In a clinical
study, Lamarche and colleagues24 reported successfulgery c May 2011
Abbreviations and Acronyms
ACT ¼ activated clotting time
APC ¼ activated protein C
CPB ¼ cardiopulmonary bypass
DIP ¼ diisopropyl fluorophosphate
EPCR ¼ endothelial protein C receptor
ICAM ¼ intercellular adhesion molecule
IL ¼ interleukin
MIP ¼ macrophage inflammatory protein
TNF ¼ tumor necrosis factor
W/D ¼ wet-to-dry
Yamazaki et al Evolving Technology/Basic Sciencetreatment of severe acute respiratory distress syndrome and
septic shock by the combined use of extracorporeal mem-
brane oxygenation and APC. Furthermore, a past trial
showed that APC significantly reduced 28-day mortality
rate when compared with placebo control in patients with
severe sepsis.14 These findings suggest that APC may
have beneficial effects on acute organ damage. However,
the effect of APC on CPB-induced acute lung injury remains
unknown.
The purposes of this study were to (1) investigate whether
the administration of APC has a protective effect on acute
lung injury in a rat model of CPB and, if so, (2) verify its
mechanism.E
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Animals and Reagents
Adult male Sprague-Dawley rats (aged 14–17 weeks, weighing 400–580
g) from a licensed vendor (Japan SLC Inc, Shizuoka, Japan) were used in the
present study. APC and diisopropyl fluorophosphate (DIP)-APC, an inac-
tive derivative of APC, were provided by the Chemo-sero-therapeutic Re-
search Institute, Kumamoto, Japan. Rats were randomized to receive
intravenous bolus of vehicle, 0.1 mg/kg DIP-APC, or 0.1 mg/kg APC
10 minutes before the initiation of CPB. This protocol resulted in the
creation of 3 groups: rats given vehicle before CPB (control group,
n ¼ 6), rats given DIP-APC (DIP group, n ¼ 6) before CPB, and rats given
APC (APC group, n ¼ 6) before CPB. The Animal Care Committee of the
National Cardiovascular Center approved this experimental protocol.
Surgical Procedure
Animal procedure was a modification of the technique described previ-
ously.15 In brief, with the animals under anesthesia via intraperitoneally ad-
ministered pentobarbital sodium (50 mg/kg) and artificial ventilation at
a tidal volume of 8 mL/kg, the right jugular vein and left carotid artery
were exposed for CPB. Then, an 18-gauge cannula with side holes and
a 22-gauge cannula were placed for venous drainage and arterial blood re-
turn, respectively. A 22-gauge cannula was inserted into the right femoral
vein to infuse saline with 5% bovine serum albumin, and a 24-gauge can-
nula was inserted into the femoral artery to monitor arterial blood pressure.
The bypass circuit was primed with 9 mL of saline with 5% bovine serum
albumin. After administration of heparin (200 U/kg), CPB was established
with the perfusion rate maintained at 60 mL/kg/min for 60 minutes. Just be-
fore the establishment of CPB, clamping of the left pulmonary hilum was
performed via anterolateral thoracotomy to simulate the lung conditionThe Journal of Thoracic and Carwhen total extracorporeal circulation was performed, and the tidal volume
was decreased to 6 mL/kg during CPB. When CPB was terminated, the pul-
monary clamp was released and the tidal volume was returned to the initial
level. The rat was observed for another 60 minutes after CPB. Arterial blood
samples were obtained 3 times (before CPB, at the end of CPB, and at the
end of the experiment) to measure arterial oxygen pressure and blood hemo-
globin level.
Wet-to-Dry Weight Ratio of Left Lung
The left lung was excised immediately after animal sacrifice and divided
into 3 parts. The superior third was weighed before and after desiccation in
a dry oven at 70C, and wet-to-dry (W/D) weight ratio was calculated as
a marker for lung edema.
Measurement of Lung Cytokine Content
The middle third of the left lung sample was used to measure the lung
contents of cytokines. The sample was homogenized in 0.5 mL
phosphate-buffered saline containing a protease inhibitor, sonicated, and
then centrifuged at 10,000 rpm for 20 minutes at 4C. The supernatants
were stored at80C until the cytokines were measured. Lung levels of
rat TNF-a, IL-1b, and macrophage inflammatory protein (MIP)-2 were
measured using corresponding enzyme-linked immunosorbent assay kits
(BioSource International, Inc, Camarillo, Calif). The results were corrected
by the protein content determined by the Bradford method.18
Expression of Adhesion Molecules on Circulating
Neutrophils
The expression of CD11b and CD62L on the neutrophil surface was an-
alyzed by fluorescence-activated cell sorting (FACS SCAN flow cytometer;
Becton Dickinson, San Jose, Calif) before CPB, at the end of CPB, and
at the end of the experiment. Whole blood was incubated with
phycoerythrin-conjugated anti-rat CD11b (Serotec Ltd, Oxford, England)
and fluorescein isothiocyanate-conjugated anti-rat CD62L (BD Bioscience
Pharmingen, San Diego, CA). Erythrocytes were then destroyed by incuba-
tion with lysing solution (BD Bioscience Pharmingen). After washing twice
with phosphate-buffered saline and centrifuge, neutrophils were fixed with
CELLFIX (Becton Dickinson). Isotype-identical antibodies served as
controls.
Activated Clotting Time
The measurement of activated clotting time (ACT) (Hemocron Jr Signa-
ture; International Technidyne Corporation, Edison, NJ) was performed be-
fore CPB and at the end of the experiment. In the APC and DIP groups, the
first blood samples were collected 10 minutes after the administration of
drugs.
Serum Fibrinogen Level
Serum level of fibrinogen was measured by the thrombin method at the
end of the experiment by SRL, Inc, Tokyo, Japan.
Pathologic Study
The inferior third of the lung was fixed with 10% formalin, embedded in
paraffin, cut into 4-mm sections, and stained with hematoxylin–eosin for
pathologic study.
Statistical Analysis
Numeric values are expressed as mean  standard error of the mean un-
less otherwise indicated. Comparisons of parameters among the 3 groups
were made using 1-way analysis of variance, followed by the Newman–
Keuls test. Comparisons of changes in parameters among the 3 groups
were made by 2-way analysis of variance for repeated measures, followed
by the Newman–Keuls test.diovascular Surgery c Volume 141, Number 5 1247
FIGURE 1. Microphotograph of the left lung. The left lung section in each
groupwas stainedwith hematoxylin–eosin. Lungs in the control andDIP groups
show interstitial edema, alveolar hemorrhage, and severe neutrophil accumula-
tion. Inflammatory change in the APC group lung is minimized. Original mag-
nification:2003.Blackbar¼50mm.Control (A),DIP (B), andAPC(C)groups.
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Histologic and Functional Improvement of the Lung
by Activated Protein C
Microscopic observation of lung tissue revealed intersti-
tial edema, alveolar hemorrhage, and infiltration of polymor-1248 The Journal of Thoracic and Cardiovascular Surphonuclear leukocytes in the control and DIP groups. APC
administration markedly minimized these abnormalities
(Figure 1). The CPB itself and ischemia of the left lung dur-
ing CPB caused the increase in peak airway pressure after-
ward. However, peak airway pressure in the APC group
remained at a plateau and tended to be lower than that in
the control and DIP groups 60 minutes after reperfusion
(APC: 11.8  0.6 vs control: 13.5  0.8 and DIP: 13.0 
0.5 cmH2O, Figure 2, A). The arterial PO2 level in the control
and DIP groups decreased significantly to 226  55 mm Hg
and 233  22 mm Hg, respectively, at the end of the exper-
iment, whereas it remained high in the APC group (APC:
409 33 mmHg, Figure 2, B). The APC group also showed
significantly lower W/D weight ratio than the other 2 groups
(APC: 6.2  .2 vs control: 7.7  .4 and DIP: 8.0  0..5,
P< .01, Figure 1, C), although there was no significant dif-
ference in body weight among the 3 groups.
Suppressive Effect of Activated Protein C on
Proinflammatory Cytokines
Lung content of MIP-2 in the APC group was signifi-
cantly lower than in the DIP group and relatively lower
than in the control group (APC: 0.7  0.3 vs DIP: 2.2 
0.5, P < .05, and control: 1.3  0.4 pg/mg protein,
P ¼ not significant, Figure 3, A). The lung content of
TNF-a and IL-1b in the APC group was also approximately
50% or less than in the control and DIP groups, although
this was not significant among the groups (TNF-a: APC;
5.4  1.3 vs control; 9.6  1.1 and DIP; 11.5  2.5 pg/mg
protein, P ¼ .07, Figure 3, B, and IL-1b: APC; 4.0  1.1
vs control; 8.4  2.1 or DIP; 11.4  2.8 pg/mg protein,
P ¼ .07, Figure 3, C).
Attenuation of Neutrophil Activation by Activated
Protein C
As indexes of neutrophil activation induced by CPB,
changes in the expression of surface adhesion molecules
of CD11b and CD62L were analyzed. The signal intensity
of CD11b in the control and DIP groups was markedly in-
creased at 60 and 120 minutes after the initiation of CPB
(Figure 4, A). However, administration of APC significantly
inhibited the increase in CD11b. The signal intensity of
CD62L was markedly decreased by CPB in the control
and DIP groups, whereas administration of APC completely
inhibited the decrease in CD62L 60 minutes after the initia-
tion of CPB (Figure 4, B).
Activated Clotting Time, Hemoglobin, and
Fibrinogen
Our preliminary ACT measurements in rats revealed that
the mean ACT value of non-heparinized blood was approx-
imately 100 seconds. ACTwas prolonged by the administra-
tion of heparin, and APC, unlike DIP-APC, induced further
extension of ACT (APC: 504 34 vs control: 398 22 andgery c May 2011
FIGURE 2. A, Peak airway pressure before CPB and at the end of the ex-
periment. The APC group shows a relatively lower value than the other
groups at the end of the experiment, although there are no significant differ-
ences among the groups. Results are expressed as mean standard error of
the mean (SEM). B, Arterial oxygen pressure before CPB and at the end of
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The Journal of Thoracic and CarDIP: 393  13 seconds, P< .05, Figure 5, A). At the end of
the experiment, however, ACT decreased to a similar value
in all 3 groups (control: 317  13, DIP: 288  10, APC:
331  18 seconds). Macroscopically, APC-treated rats did
not show an obvious bleeding tendency during the experi-
ments compared with other group animals. Hemoglobin
levels in all groups were approximately 14 g/dL initially
and then similarly decreased to approximately 10 g/dL after
CPB and at the end of the experiment, mainly because of he-
modilution. There was no significant difference among the
groups before CPB, after CPB, and at the end of the exper-
iment (control: 14.3  0.2, 9.0  0.2, and 9.8  0.5, DIP:
13.8  0.4, 9.8  0.6, and 10.3  0.9, APC: 14.0  0.7,
9.5  0.4, and 10.0  0.8 g/dL, respectively, Figure 5, B).
The serum fibrinogen level at the end of the experiment
did not significantly differ among the 3 groups (APC:
99  20, control: 118  7, DIP: 129  11 mg/dL,
Figure 5, C).E
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The present study demonstrated that the administration of
APC attenuated CPB-induced edematous changes and neu-
trophil sequestration in the lung, and maintained higher arte-
rial PO2 and lower W/D weight ratio after CPB compared
with vehicle or DIP-APC. We also clarified that APC atten-
uated neutrophil activation induced by CPB, as indicated by
normalized expression of CD11b and CD62L, and tended to
decrease intrapulmonary concentrations of proinflammatory
cytokines after CPB.
A previous study, using the same CPB circuit, showed
that 60 minutes of CPB induces acute lung injury afterward
and that the inhibition of neutrophil activation by phospho-
diesterase type 4 inhibitor or anti-neutrophil monoclonal an-
tibody clearly reduced post-CPB lung injury, indicating
neutrophils activated by CPB play a pivotal role in the pro-
cess of post-CPB lung injury.15 We used this rat CPB model
to evaluate lung protection by APC. Lung injury that oc-
curred in the vehicle (control) group was compatible with
previous observations. APC administration before CPB
markedly attenuated physiologic and pathologic pulmonary
deterioration after CPB. The results clearly revealed the in
vivo anti-inflammatory impact of APC.
We then examined underlyingmechanisms of lung protec-
tion by APC. The anti-inflammatory activity of APC is
known to be EPCR dependent. EPCR is primarily found
on endothelial cells of arteries, veins, and capillaries.the experiment. The APC group shows a significantly higher value than the
other groups at the end of the experiment. Results are expressed as mean 
SEM. #P<.01 versus the control or DIP group. C, W/D weight ratio of the
left lung. The APC group shows a significantly lower value than the other
groups. Results are expressed as mean  SEM. #P<.01 versus the control
or DIP group. APC, Activated protein C; CPB, cardiopulmonary bypass;
DIP, diisopropyl fluorophosphate; W/D, wet-to-dry.
:
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FIGURE 3. A, Tissue MIP-2 concentration in the left lung. The APC
group shows a relatively lower value than the control group and a signifi-
cantly lower value than the DIP group. Results are expressed as mean 
SEM. #P< .01 versus the DIP group. B, Tissue TNF-a concentration in
Evolving Technology/Basic Science Yamazaki et al
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SEPCR has also been confirmed to be expressed on the mem-
brane of monocytes, CD56þnatural killer cells, neutrophils,
and eosinophils.13,16 Sturn et al17 showed that APC directly
inhibits chemotaxis of stimulated neutrophils by means of
binding to EPCR in vitro. However, the in vivo effects of
APC on neutrophils still remains unknown. This study ana-
lyzed changes in the signal intensity of adhesion molecules,
CD62L andCD11b, on neutrophil surface by flow cytometry
to evaluate their excitation. CD62L, a member of the selectin
family, is present on the surface of circulatory non-activated
leukocytes.19,20 The molecule CD11b is classified as one of
the leukocyte integrins, which are largely responsible for
increasing adhesion and transendothelial migration of
neutrophils through interactions with their endothelial
counter-receptors, ICAM-1 and ICAM-2.21 In general,
CD62L is rapidly shed after neutrophil activation with con-
comitant up-regulation of Mac-1 (CD11b/CD18).4,19
During CPB, neutrophils are activated by the contact with
the surface of the bypass circuit, and chemical mediators,
such as TNF-a and IL-8 (MIP-2), also stimulate neutrophils.
Although direct effects of APC on CD11b and CD62L re-
main unknown, Franscini and colleagues12 showed that
APC down-regulates expression of ICAM-1 stimulated by
IL-1b and TNF-a. Our observation that the administration
of APC normalized the expression of CD11b and CD62L af-
ter CPB indicates that APC effectively down-regulates neu-
trophil functions. Notably, in our previous studies, the
expression of CD62L increased after CPB and neutrophil in-
hibitors did not alter the trend. We speculated that CPB did
not reduce CD62L expression in those study settings because
of the influence of new neutrophils from bone marrow. The
difference between this study and Franscini and colleagues’
is the surgical procedure for the setup of CPB. We did not
perform a sternotomy to insert a drainage line but introduced
a catheter from the right jugular vein to the right atrium in-
stead. This minor improvement, however, should signifi-
cantly reduce bone marrow stimulation to release
neutrophils.
Proinflammatory cytokines are important mediators in
various disease processes. An increase in the lung contents
of TNF-a, IL-1, and IL-8 during and after CPB was reported
in several studies.1,15 A recent in vivo study showed that
APC inhibits lipopolysaccharide-induced production of
TNF-a by the inhibiting activation of both nuclear factor-
kB and activator protein-1 in monocytes.22 The ability ofthe left lung. The APC group shows a relatively lower value than the other
groups, although there are no significant differences among the groups. Re-
sults are expressed as mean  SEM. C, Tissue IL-1b concentration in the
left lung. The APC group shows a relatively lower value than the other
groups, although there are no significant differences among the groups. Re-
sults are expressed as mean  SEM. DIP, Diisopropyl fluorophosphate;
APC, activated protein C; TNF, tumor necrosis factor; MIP, macrophage
inflammatory protein; IL, interleukin.
:
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FIGURE 4. A, CD11b expression on circulating neutrophils. Percentage
change in geometric mean from the value before CPB was calculated.
The APC group maintains leveled CD11b expression at all time points,
whereas expression in the control and DIP groups increases approximately
double at 60 and 120 minutes after the initiation of CPB. Results are
expressed as mean SEM. *P<.05 versus the DIP group. **P<.05 versus
the control or DIP group. B, CD62L expression on circulating neutrophils.
Percentage change in geometric mean from the value before CPB was cal-
culated. CD62L expression remains level in the APC throughout the exper-
iment, whereas expression in the control and DIP groups gradually
decreases to approximately 50% at 120 minutes after the initiation of
CPB. Results are expressed as mean  SEM. #P< .01 versus the control
or DIP group. *P< .05 versus the DIP group. CPB, Cardiopulmonary by-
pass; DIP, diisopropyl fluorophosphate; APC, activated protein C.
FIGURE 5. A, ACT before CPB and at the end of the experiment. The
APC group shows a significantly higher value than the others only before
CPB. The values decrease in all groups at the end of the experiment and be-
come similar to one another. Results are expressed as mean  SEM.
*P<.05 versus the control or DIP group. B, Blood hemoglobin level before
CPB, after CPB, and at the end of the experiment. In all groups, the values
after CPB and at the end of the experiments similarly decrease to approxi-
mately 70% of initial values. There are no significant differences among the
groups at any time point. Results are expressed as mean  SEM. C, Serum
fibrinogen level at the end of the experiment. There are no significant differ-
ences among the groups. Results are expressed as mean  SEM. ACT, Ac-
tivated clotting time; DIP, diisopropyl fluorophosphate; APC, activated
protein C; CPB, cardiopulmonary bypass.
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also reported using the immortalized human monocytic cell
line.23 In the present study, mean values of intrapulmonary
TNF-a, IL-1b, and MIP-2 in the APC group wereThe Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 5 1251
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Sapproximately 50% of those in the other groups, although
the statistical significance was not recognized because of
a relatively wider sample distribution. TNF-a and IL-1b
are secreted primarily by activated monocytes and cause
subsequent activation of neutrophils, macrophages, and en-
dothelial cells. MIP-2 is considered to be a rat homologue of
IL-8, a potent neutrophil chemoattractant. These findings
imply the inhibitory effect of APC on CPB-induced produc-
tion of TNF-a, IL-1b, andMIP-2, which also may contribute
to neutrophil activation and sequestration.
Exogenously administeredAPCmay affect the hemostatic
function, because APC is an endogenous anticoagulant. In-
deed, elongated ACT by heparin was further prolonged by
the administration of APC. The effect of APC onACT value,
however, had declined by the end of the experiment, and no
obvious bleeding tendency was seen in the APC group in
terms of hemoglobin levels and macroscopic findings. In ad-
dition, serum fibrinogen level at the end of the experiment
did not significantly differ among the 3 groups. Taken to-
gether, a bolus injection of the APC dose used in this study
did not seem to significantly worsen or improve clinical co-
agulability during and after CPB in this model. In contrast,
the inhibitory effect of APC on neutrophil activation lasted
more than 120 minutes.
CONCLUSIONS
APC prevented acute lung injury induced by CPB at least
in part through the inhibition of neutrophil activation, possi-
bly via the attenuation of cytokine production in this setting.
The administration of APC may be a promising therapeutic
strategy for the treatment of postoperative complications
induced by CPB.
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